Search
Emergent BioSolutions Inc
EBSAdd to Watchlist
8.130USD
+0.190+2.39%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
421.13MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+2.39%
5 Days
-9.16%
1 Month
-7.72%
6 Months
-19.66%
Year to Date
-34.22%
1 Year
+22.44%
TradingKey Stock Score of Emergent BioSolutions Inc
Currency: USD Updated: 2026-05-15Key Insights
Emergent BioSolutions Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Emergent BioSolutions Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Emergent BioSolutions Inc Highlights
StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -58.47, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.30M shares, decreasing 7.38% quarter-over-quarter.
Held by Barrow Hanley
Star Investor Barrow Hanley holds 80.65K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+51.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Emergent BioSolutions Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Emergent BioSolutions Inc Info
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOPapa (Joseph C)
Websitehttps://emergentbiosolutions.com/
Related Instruments
-1.67%
+1.29%
+0.97%
-0.47%
+0.72%
+1.06%
-0.59%
+0.07%
-1.03%
0.00%
+0.54%
-0.08%
+1.99%
+1.19%
+2.02%
0.00%
-9.82%
-0.24%
-2.88%
+2.34%Popular Instruments
102.193
-0.263 (-0.26%)
297.840
-2.390 (-0.80%)
222.320
-3.000 (-1.33%)
4570.700
+4.580 (+0.10%)
458.680
-23.340 (-4.84%)
1333.010
-74.600 (-5.30%)
681.540
-43.120 (-5.95%)
396.940
+0.160 (+0.04%)
77153.410
+273.490 (+0.36%)
409.990
-12.250 (-2.90%)
